UBS lowered the firm’s price target on ALX Oncology (ALXO) to $1 from $1.20 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology highlights preclinical data, development plans for ALX2004
- Strategic Shift and Promising Pipeline Drive Buy Rating for ALX Oncology Holdings
- ALX Oncology price target lowered to $2 from $5 at H.C. Wainwright
- ALX Oncology Reports Q1 2025 Financial Results
- ALX Oncology reports Q1 EPS (58c) vs (71c) last year